Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report
Journal of Medical Virology2020Vol. 93(3), pp. 1678–1686
Citations Over TimeTop 14% of 2020 papers
Ali S. Omrani, Ahmed Zaqout, Anas Baiou, Joanne Daghfal, Naser Elkum, Rand A. Alattar, Dana Bakdach, Hatem Abusriwil, Abdalrahman M. Mostafa, Bassem Al Hariri, Naseem Ambra, Mohamed Y. Khatib, Ali M. Eldeeb, Zeyd Merenkov, Zeinab Fawzi, Saloua Hmissi, Ali Ait Hssain, Peter Coyle, Hussam Al Soub, Muna Almaslamani, Abdullatif Al‐Khal
Abstract
In severe COVID-19, convalescent plasma therapy was not associated with clinical benefits. Randomized trials are required to confirm our findings.
Related Papers
- → Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV)(2020)32 cited
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management(2022)21 cited
- → Confirmation of SARS-CoV-2 airborne dissemination indoors using “COVID-19 traps”(2021)4 cited